Skip to content


United States

TARPEYO has received full approval by the United States (US) Food and Drug Administration (FDA) for use in the US.
It is marketed in the US exclusively by Calliditas Therapeutics AB.


Kinpeygo® has been granted conditional marketing authorization by the European Commission (EC). It will be marketed in the European Economic Area (EEA), United Kingdom and Switzerland exclusively by STADA Arzneimittel AG.